Study calls for tailored treatments for regional HIV variations, Pg11.

Key Highlights:

• Indian research reveals that the effectiveness of antibody-based HIV treatments varies based on the virus's geographic origin.
• The study emphasizes the need to optimize future HIV vaccines and antibody treatments for different regions.
• HIV-1 Clade C, the most common variant globally and in India, was found to have genetic and antibody response differences between Indian and African strains.
• Researchers studied HIV across nine regions in India to assess the effectiveness of broadly-neutralizing antibodies (bnAbs).

Detailed Insights:

• Injectable antibodies are being tested as a preventive measure against HIV infection due to the absence of a vaccine.
• HIV mutates rapidly, creating diverse versions that most antibodies cannot neutralize, but scientists have identified broadly-neutralizing antibodies (bnAbs) effective against many variants.
• The multi-center study, supported by the DBT/Wellcome Trust India Alliance, found that HIV-1 clade C strains in India differ genetically and in antibody response from those in Africa.
• Monitoring circulating HIV strains helps evaluate the effectiveness of leading bnAbs against HIV-1 subtype C strains in India and South Africa.
• Region-specific HIV prevention strategies, including vaccines and passive immunization, are crucial for high-risk individuals.
• Monoclonal antibodies, administered with antiretroviral therapy, can significantly reduce infection rates among high-risk groups.

Scientific/Technical Concepts Involved:

• HIV (Human Immunodeficiency Virus): A virus that attacks the body's immune system, leading to AIDS if untreated.
• Antibodies: Proteins produced by the immune system to neutralize pathogens like viruses and bacteria.
• Broadly-Neutralizing Antibodies (bnAbs): Rare antibodies that can neutralize a wide range of HIV variants.
• HIV-1 Clade C: The most prevalent HIV variant globally, accounting for nearly half of all infections.